IL6 and COVID-19: Our findings may help explain the recent results from randomized studies whereby neutralization of IL-6 activity by tocilizumab did not show a benefit in mortality or clinical recovery in patients with severe COVID-19 (Hermine et al., 2020; Salvarani et al., 2020; Stone et al., 2020).